Cargando…
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
IMPORTANCE: The 2-year efficacy and safety of combination therapy of ranibizumab administered together with verteporfin photodynamic therapy (vPDT) compared with ranibizumab monotherapy in participants with polypoidal choroidal vasculopathy (PCV) are unclear. OBJECTIVE: To compare treatment outcomes...
Autores principales: | Lim, Tock H., Lai, Timothy Y. Y., Takahashi, Kanji, Wong, Tien Y., Chen, Lee-Jen, Ruamviboonsuk, Paisan, Tan, Colin S., Lee, Won Ki, Cheung, Chui Ming Gemmy, Ngah, Nor Fariza, Patalauskaite, Ramune, Margaron, Philippe, Koh, Adrian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366282/ https://www.ncbi.nlm.nih.gov/pubmed/32672800 http://dx.doi.org/10.1001/jamaophthalmol.2020.2443 |
Ejemplares similares
-
Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
por: Takahashi, Kanji, et al.
Publicado: (2018) -
Polypoidal Choroidal Vasculopathy in Asians
por: Wong, Chee Wai, et al.
Publicado: (2015) -
Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
por: Fernández, Maribel, et al.
Publicado: (2012) -
EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study
por: Tan, Colin S., et al.
Publicado: (2016) -
EVEREST study report 4: Fluorescein angiography features predictive of polypoidal choroidal vasculopathy
por: Tan, Colin S., et al.
Publicado: (2019)